ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Acadia Pharma (ACAD) Tops Q4 EPS by 5c
February 26, 2019 4:13 PM ESTAcadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.50), $0.05 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $59.6 million versus the consensus estimate of $59.46 million.
Our team successfully executed on all three of our strategic pillars in 2018. We grew NUPLAZID in Parkinsons... More
